Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study.
Autor: | Fariña-Sarasqueta A; Department of Molecular Diagnostics, PAMM Laboratory of Pathology, Michelangelolaan 2, 5623 EJ Eindhoven, The Netherlands., van Lijnschoten G, Rutten HJ, van den Brule AJ |
---|---|
Jazyk: | angličtina |
Zdroj: | Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2010 Nov; Vol. 66 (6), pp. 1167-71. Date of Electronic Publication: 2010 Jul 28. |
DOI: | 10.1007/s00280-010-1403-0 |
Abstrakt: | Purpose: The role of pharmacogenetics in chemotherapy response in colon carcinoma is controversial. We studied the value of known SNPs in genes involved in 5-FU metabolism as biomarkers of chemotherapy response in patients with stage III colon carcinoma. Methods: DNA was isolated from normal colonic tissue of 60 patients with stage III colon carcinoma treated adjuvantly with 5-FU combined with leucovorin. The tested SNPs were validated SNPs on the OPRT, TYMS and DPYD genes and a synonymous SNP on the TYMP gene. Real-time PCR, sequencing and RFLP were used for genotyping. Results: None of the studied genotypes was associated with any of the tumor or patient characteristics. Moreover, none of the genotypes studied had effect on patient survival. Conclusion: In conclusion, the tested SNPs are not biomarkers of chemotherapy response in our stage III colon cancer patients group. |
Databáze: | MEDLINE |
Externí odkaz: |